Europlasma SA (ALEUP) AI Stock Analysis

• Market Cap: €1.49M
• Dividend Yield: N/A
• Average Volume (3M): 34.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: 151.29%
• EPS Growth: 99.50%
• Country: FR
• Employees: 184
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Waste Management
• EPS (TTM): -199.71
• Shares Outstanding: 1,501,802
• 10 Day Avg. Volume: 46,660
• 30 Day Avg. Volume: 34,817
• PEG Ratio: 59.35
• Price to Book (P/B): -8.72K
• Price to Sales (P/S): 2137.67
• P/FCF Ratio: -6.99K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: €0.00 ▼(-100.00% Downside)

Europlasma SA's overall stock score is heavily impacted by its poor financial performance, with significant challenges in profitability, financial stability, and cash flow management. Technical analysis further indicates a bearish trend, with oversold conditions. The negative P/E ratio and lack of dividends highlight valuation concerns. These factors collectively result in a low overall stock score.

Europlasma SA Business Overview & Revenue Model

Company Description

Europlasma S.A., together with its subsidiaries, engages in developing, constructing, and operating of the plasma torch system for industrial applications in France. It offers plasma solutions for gas and hazardous wastes. The company also engages in the production of renewable energy from waste and biomass; and provides asbestos waste treatment services, such as collection, transport, neutralization, and recovery services for hazardous waste. Europlasma S.A. was founded in 1992 and is based in Pessac, France.

How the Company Makes Money

Europlasma generates revenue through the sale of its plasma technology systems and the operation of waste treatment facilities. Key revenue streams include the direct sale of plasma gasification units to businesses and municipalities, as well as long-term contracts for waste processing services. The company may also benefit from government grants and incentives aimed at promoting clean energy technologies. Significant partnerships with industrial clients and collaborations with environmental agencies contribute to its earnings, enhancing the company's market positioning and enabling it to secure ongoing projects.

Europlasma SA Financial Statement Overview

Summary

Europlasma SA is facing significant financial challenges. Despite strong revenue growth, profitability remains elusive due to high operational costs. The balance sheet shows financial instability with negative equity and high liabilities. Cash flow analysis indicates reliance on external financing, highlighting the need for strategic financial management to achieve sustainable growth and stability.

Income Statement

Europlasma SA's revenue has shown significant growth, increasing by over 175% from 2023 to 2024. However, profitability remains a concern with negative gross and net profit margins. The EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges. The company needs to focus on cost management to improve profitability.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, but high liabilities relative to assets suggest potential leverage risks. The negative equity ratio further emphasizes the need for financial restructuring.

Cash Flow

Europlasma SA's cash flow analysis reveals negative operating and free cash flows, reflecting difficulties in generating cash from operations. The free cash flow to net income ratio is negative, aligning with persistent net losses. Positive financing cash flow indicates reliance on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.45M	15.41M	14.52M	9.80M	3.79M
Gross Profit	-20.59M	-17.41M	-13.75M	-9.59M	-8.82M
EBITDA	-3.36M	-3.84M	-5.30M	-3.14M	5.94M
Net Income	-15.29M	-14.74M	-15.92M	-12.67M	-9.88M
Balance Sheet
Total Assets	62.90M	45.26M	54.67M	40.44M	26.30M
Cash, Cash Equivalents and Short-Term Investments	1.75M	1.16M	2.41M	2.49M	4.17M
Total Debt	13.26M	11.47M	8.37M	4.18M	7.59M
Total Liabilities	74.05M	50.02M	48.86M	35.97M	42.75M
Stockholders Equity	-10.41M	-4.01M	6.56M	5.35M	-15.58M
Cash Flow
Free Cash Flow	-12.98M	-12.17M	-13.38M	-23.75M	-17.11M
Operating Cash Flow	-11.47M	-10.43M	-10.48M	-18.33M	-12.33M
Investing Cash Flow	-2.09M	-953.00K	-4.16M	-5.70M	-5.76M
Financing Cash Flow	14.14M	10.14M	14.56M	22.25M	19.53M

Europlasma SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AURE	―	€50.11M	50.66	―	―	-11.23%	43.27%
Sector *	―	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ALTUV	―	€21.82M	24.92	―	―	-7.99%	―
OREGE	―	€14.34M	―	―	―	103.54%	-19.23%
ALEUP	―	€1.49M	―	―	―	151.29%	99.50%